These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24696747)

  • 21. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
    Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
    J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
    McCluggage WG; Shah R; Connolly LE; McBride HA
    Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines.
    Ferretti GR; Busser B; de Fraipont F; Reymond E; McLeer-Florin A; Mescam-Mancini L; Moro-Sibilot D; Brambilla E; Lantuejoul S
    Lung Cancer; 2013 Oct; 82(1):69-75. PubMed ID: 23927885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
    Hiramatsu M; Ninomiya H; Inamura K; Nomura K; Takeuchi K; Satoh Y; Okumura S; Nakagawa K; Yamori T; Matsuura M; Morikawa T; Ishikawa Y
    Lung Cancer; 2010 Oct; 70(1):94-102. PubMed ID: 20117855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
    Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
    Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.
    Zuo Y; Zhong J; Bai H; Xu B; Wang Z; Li W; Chen Y; Jin S; Wang S; Wang X; Wan R; Xu J; Fei K; Han J; Yang Z; Bao H; Shao Y; Ying J; Song Q; Duan J; Wang J
    EBioMedicine; 2022 Aug; 82():104165. PubMed ID: 35901658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry.
    Zhang J; Xiang C; Han Y; Teng H; Li X; Shao J; Zhu L; Han-Zhang H; Ye J; Yu K
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):269-279. PubMed ID: 30415301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
    Kim JO; Lee J; Shin JY; Oh JE; Jung CK; Park JK; Sung SW; Bae SJ; Min HJ; Kim D; Park JY; Kang JH
    Diagn Pathol; 2015 Aug; 10():143. PubMed ID: 26268359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
    Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
    Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort.
    Mansuet-Lupo A; Bobbio A; Blons H; Becht E; Ouakrim H; Didelot A; Charpentier MC; Bain S; Marmey B; Bonjour P; Biton J; Cremer I; Dieu-Nosjean MC; Sautès-Fridman C; Régnard JF; Laurent-Puig P; Alifano M; Damotte D
    Chest; 2014 Sep; 146(3):633-643. PubMed ID: 24676429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.
    Monaco SE; Nikiforova MN; Cieply K; Teot LA; Khalbuss WE; Dacic S
    Hum Pathol; 2010 Jan; 41(1):94-102. PubMed ID: 19740513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.
    Park SY; Kim BH; Kim JH; Lee S; Kang GH
    Arch Pathol Lab Med; 2007 Oct; 131(10):1561-7. PubMed ID: 17922593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology.
    Nottegar A; Tabbò F; Luchini C; Brunelli M; Bria E; Veronese N; Santo A; Cingarlini S; Gilioli E; Ogliosi C; Eccher A; Montagna L; Pedron S; Doglioni C; Cangi MG; Inghirami G; Chilosi M
    Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):383-387. PubMed ID: 27753661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
    Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
    Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology.
    Rossi G; Mengoli MC; Cavazza A; Nicoli D; Barbareschi M; Cantaloni C; Papotti M; Tironi A; Graziano P; Paci M; Stefani A; Migaldi M; Sartori G; Pelosi G
    Virchows Arch; 2014 Jan; 464(1):61-8. PubMed ID: 24221342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy.
    Garajová I; Funel N; Fiorentino M; Agostini V; Ferracin M; Negrini M; Frassineti GL; Gavelli G; Frampton AE; Biasco G; Giovannetti E
    Clin Epigenetics; 2015; 7():129. PubMed ID: 26677401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.